ZA945032B - Pyrimidones and imidazolinones for treatment of shock - Google Patents

Pyrimidones and imidazolinones for treatment of shock

Info

Publication number
ZA945032B
ZA945032B ZA945032A ZA945032A ZA945032B ZA 945032 B ZA945032 B ZA 945032B ZA 945032 A ZA945032 A ZA 945032A ZA 945032 A ZA945032 A ZA 945032A ZA 945032 B ZA945032 B ZA 945032B
Authority
ZA
South Africa
Prior art keywords
pyrimidones
imidazolinones
shock
treatment
Prior art date
Application number
ZA945032A
Other languages
English (en)
Inventor
Victoria L Cohan
Eric R Pettipher
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA945032B publication Critical patent/ZA945032B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA945032A 1993-07-13 1994-07-12 Pyrimidones and imidazolinones for treatment of shock ZA945032B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/091,693 US5482944A (en) 1993-07-13 1993-07-13 Pyrimidones and imidazolinones for treatment of shock

Publications (1)

Publication Number Publication Date
ZA945032B true ZA945032B (en) 1996-01-12

Family

ID=22229174

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA945032A ZA945032B (en) 1993-07-13 1994-07-12 Pyrimidones and imidazolinones for treatment of shock

Country Status (12)

Country Link
US (1) US5482944A (hu)
EP (1) EP0636369A1 (hu)
JP (1) JP2899861B2 (hu)
KR (1) KR950002763A (hu)
CN (1) CN1105858A (hu)
AU (1) AU6741294A (hu)
CA (1) CA2127735A1 (hu)
HU (1) HUT67598A (hu)
IL (1) IL110243A0 (hu)
MX (1) MX9405318A (hu)
RU (1) RU94026088A (hu)
ZA (1) ZA945032B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315797A1 (de) * 1983-04-30 1984-10-31 Beiersdorf Ag, 2000 Hamburg Substituierte phenyl-2-(1h)-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
RU2104306C1 (ru) * 1989-11-13 1998-02-10 Пфайзер Инк. Способ получения оптически активного (2s)- или (2r)-эндо-бицикло[2.2.1]гептан-2-ола, способ получения 5-(3-[(2r)-экзо-бицикло[2.2.1]гепт-2-илокси]-4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-она, оптически активный 5-(3-[экзо-бицикло[2.2.1]гепт-2-илокси]4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-он, оптически активные промежуточные соединения и способ их получения
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds

Also Published As

Publication number Publication date
KR950002763A (ko) 1995-02-16
CA2127735A1 (en) 1995-01-14
RU94026088A (ru) 1996-05-20
MX9405318A (es) 1995-01-31
AU6741294A (en) 1995-01-27
HUT67598A (en) 1995-04-28
CN1105858A (zh) 1995-08-02
EP0636369A1 (en) 1995-02-01
HU9402081D0 (en) 1994-09-28
JP2899861B2 (ja) 1999-06-02
JPH08208473A (ja) 1996-08-13
US5482944A (en) 1996-01-09
IL110243A0 (en) 1994-10-21

Similar Documents

Publication Publication Date Title
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
GB9310241D0 (en) Cosmetic treatment of substrates
ZA945426B (en) Treatment of tachyarrhytmias of supraventricular origin
HU9503451D0 (en) The treatment of small animals
GB9324773D0 (en) Treatment of cellulose
HU9402361D0 (en) New makrolides and use of them
ZA957113B (en) Use of N-substituted pyhenothiazines
GB9211736D0 (en) Allergic treatment
ZA945032B (en) Pyrimidones and imidazolinones for treatment of shock
GB9317943D0 (en) Treatment of laminitis
GB9415901D0 (en) Novel compounds and treatment
GB2284739B (en) Processing of whelks
GB9415900D0 (en) Novel compounds and treatment
ZA941939B (en) Therapeutic triazine compounds and use
GB2275314B (en) Support member and method of use
GB9317989D0 (en) Treatment of laminitis
GR3035528T3 (en) Use of triazine compounds for the treatment of memory and learning disorders
GB9412413D0 (en) Boiler treatment and novel compounds therefor
GB9321592D0 (en) Novel compounds and treatment
GB9302289D0 (en) Novel compounds and treatment
GB9302314D0 (en) Novel compounds and treatment
GB9321591D0 (en) Novel compounds and treatment
GB9321971D0 (en) Method of treatment
GB9321796D0 (en) Method of treatment
GB9326020D0 (en) Novel method of treatment